Allarity Therapeutics vs Mereo BioPharma
ALLR and MREO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and MREO compare
Mereo BioPharma is the larger company, worth 17 times as much as Allarity Therapeutics ($244M against $13.9M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | MREO |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $244M |
| Share price | $0.875 | $0.305 |
| Change, 1 year | −26.5% | −82.9% |
| Change, 5 years | – | −83.9% |
| Beta (5Y) | 1.41 | 2.15 |
| Employees | 8 | 39 |
| StockData Score | ||
| Total score | 1 | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.9× (better) | 10.3× |
| FCF yield | – | −9.1% |
| Profitability | ||
| Return on equity | −157% | −76.6% (better) |
| Return on invested capital | −957% | – |
| Financial health | ||
| Debt / equity | 5.90 | – |
| Interest coverage | −10.1× (better) | −440.6× |
| Current ratio | 1.11 | 5.22 (better) |
| Altman Z-score | −6.64 | −2.20 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 6.4% | – |
| Shareholder yield | 6.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 8.1% | 7.1% |
| Held by insiders | 6.3% | 0.18% |
| Short interest, % of float | 1.5% | – |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- MREO stock overview
- MREO income statement
- MREO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.